10955 Vista Sorrento Parkway
Suite 200
San Diego, CA 92130
United States
858-751-4493
https://www.januxrx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 64
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. David Alan Campbell Ph.D. | President, CEO & Director | 852.5k | N/A | 1960 |
Mr. Byron Robinson J.D., Ph.D. | Chief Strategy Officer | 606.8k | N/A | 1965 |
Mr. Tighe M. Reardon C.F.A., CPA | Acting Chief Financial Officer | N/A | N/A | 1977 |
Mr. Charles M. Winter | Chief Technical Officer | N/A | N/A | 1969 |
Dr. Tommy Diraimondo Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Mr. James Pennington | General Counsel | N/A | N/A | N/A |
Ms. Brenda Van Vreeswyk | Head of Human Resources | N/A | N/A | N/A |
Mr. Andy Hollman Meyer | Chief Business Officer | N/A | N/A | 1984 |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 8; Compensation: 9.